XML 27 R17.htm IDEA: XBRL DOCUMENT
v3.23.2

Equity | 6 Months Ended
--- | ---
Jun. 30, 2023
Equity [Abstract] |
Equity | Equity
| Three Months Ended June 30,
| Common Stock | Other Paid-In Capital | Retained Earnings | Accumulated Other Comprehensive Loss | Treasury Stock | Non- controlling Interests | Total
($ and shares in millions except per share amounts) | Shares | Par Value | Shares | Cost
Balance at April 1, 2022 | 3,577 |  | $ | 1,788 |  | $ | 44,275 |  | $ | 56,252 |  | $ | (4,369) |  | 1,049 |  | $ | (57,063) |  | $ | 70 |  | $ | 40,953 |
Net income attributable to Merck & Co., Inc. | — |  | — |  | — |  | 3,944 |  | — |  | — |  | — |  | — |  | 3,944 |
Other comprehensive income, net of taxes | — |  | — |  | — |  | — |  | 42 |  | — |  | — |  | — |  | 42 |
Cash dividends declared on common stock ($0.69 per share) | — |  | — |  | — |  | (1,759) |  | — |  | — |  | — |  | — |  | (1,759) |
Share-based compensation plans and other | — |  | — |  | (160) |  | — |  | — |  | (5) |  | 293 |  | — |  | 133 |
Net income attributable to noncontrolling interests | — |  | — |  | — |  | — |  | — |  | — |  | — |  | 5 |  | 5 |
Balance at June 30, 2022 | 3,577 |  | $ | 1,788 |  | $ | 44,115 |  | $ | 58,437 |  | $ | (4,327) |  | 1,044 |  | $ | (56,770) |  | $ | 75 |  | $ | 43,318 |
Balance at April 1, 2023 | 3,577 |  | $ | 1,788 |  | $ | 44,467 |  | $ | 62,039 |  | $ | (4,883) |  | 1,040 |  | $ | (56,577) |  | $ | 71 |  | $ | 46,905 |
Net loss attributable to Merck & Co., Inc. | — |  | — |  | — |  | (5,975) |  | — |  | — |  | — |  | — |  | (5,975) |
Other comprehensive loss, net of taxes | — |  | — |  | — |  | — |  | (17) |  | — |  | — |  | — |  | (17) |
Cash dividends declared on common stock ($0.73 per share) | — |  | — |  | — |  | (1,866) |  | — |  | — |  | — |  | — |  | (1,866) |
Treasury stock shares purchased | — |  | — |  | — |  | — |  | — |  | 3 |  | (338) |  | — |  | (338) |
Share-based compensation plans and other | — |  | — |  | (248) |  | — |  | — |  | (5) |  | 303 |  | — |  | 55 |
Net income attributable to noncontrolling interests | — |  | — |  | — |  | — |  | — |  | — |  | — |  | 3 |  | 3 |
Distributions attributable to noncontrolling interests | — |  | — |  | — |  | — |  | — |  | — |  | — |  | (25) |  | (25) |
Balance at June 30, 2023 | 3,577 |  | $ | 1,788 |  | $ | 44,219 |  | $ | 54,198 |  | $ | (4,900) |  | 1,038 |  | $ | (56,612) |  | $ | 49 |  | $ | 38,742 |
| Six Months Ended June 30,
| Common Stock | Other Paid-In Capital | Retained Earnings | Accumulated Other Comprehensive Loss | Treasury Stock | Non- controlling Interests | Total
($ and shares in millions except per share amounts) | Shares | Par Value | Shares | Cost
Balance at January 1, 2022 | 3,577 |  | $ | 1,788 |  | $ | 44,238 |  | $ | 53,696 |  | $ | (4,429) |  | 1,049 |  | $ | (57,109) |  | $ | 73 |  | $ | 38,257 |
Net income attributable to Merck & Co., Inc. | — |  | — |  | — |  | 8,254 |  | — |  | — |  | — |  | — |  | 8,254 |
Other comprehensive income, net of taxes | — |  | — |  | — |  | — |  | 102 |  | — |  | — |  | — |  | 102 |
Cash dividends declared on common stock ($1.38 per share) | — |  | — |  | — |  | (3,513) |  | — |  | — |  | — |  | — |  | (3,513) |
Share-based compensation plans and other | — |  | — |  | (123) |  | — |  | — |  | (5) |  | 339 |  | — |  | 216 |
Net income attributable to noncontrolling interests | — |  | — |  | — |  | — |  | — |  | — |  | — |  | 2 |  | 2 |
Balance at June 30, 2022 | 3,577 |  | $ | 1,788 |  | $ | 44,115 |  | $ | 58,437 |  | $ | (4,327) |  | 1,044 |  | $ | (56,770) |  | $ | 75 |  | $ | 43,318 |
Balance at January 1, 2023 | 3,577 |  | $ | 1,788 |  | $ | 44,379 |  | $ | 61,081 |  | $ | (4,768) |  | 1,039 |  | $ | (56,489) |  | $ | 67 |  | $ | 46,058 |
Net loss attributable to Merck & Co., Inc. | — |  | — |  | — |  | (3,154) |  | — |  | — |  | — |  | — |  | (3,154) |
Other comprehensive loss, net of taxes | — |  | — |  | — |  | — |  | (132) |  | — |  | — |  | — |  | (132) |
Cash dividends declared on common stock ($1.46 per share) | — |  | — |  | — |  | (3,729) |  | — |  | — |  | — |  | — |  | (3,729) |
Treasury stock shares purchased | — |  | — |  | — |  | — |  | — |  | 4 |  | (487) |  | — |  | (487) |
Share-based compensation plans and other | — |  | — |  | (160) |  | — |  | — |  | (5) |  | 364 |  | — |  | 204 |
Net income attributable to noncontrolling interests | — |  | — |  | — |  | — |  | — |  | — |  | — |  | 7 |  | 7 |
Distributions attributable to noncontrolling interests | — |  | — |  | — |  | — |  | — |  | — |  | — |  | (25) |  | (25) |
Balance at June 30, 2023 | 3,577 |  | $ | 1,788 |  | $ | 44,219 |  | $ | 54,198 |  | $ | (4,900) |  | 1,038 |  | $ | (56,612) |  | $ | 49 |  | $ | 38,742 |

X
- References No definition available. + Details
Name: | us-gaap_EquityAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for equity. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1 Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//505/tableOfContent Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16 Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18 + Details
Name: | us-gaap_StockholdersEquityNoteDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration